Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of ketamine on drug addiction in schizophrenia using the methylazoxymethanol (MAM) acetate rat model on operant IV methamphetamine (METH) self-administration. MAM was administered intraperitoneally (22 mg/kg) on gestational day 17. Locomotor activity test and later IV self-administration (IVSA) were then performed in the male offspring followed by a period of forced abstinence and relapse of METH taking. After reaching stable intakes in the relapse phase, ketamine (5 mg/kg) was administered intraperitoneally 30 min prior to the self-administration session. As documented previously, the MAM rats showed a lack of habituation in the locomotor activity test but developed stable maintenance of METH self-administration with no difference in operant behaviour to control animals. Results show that ketamine treatment significantly reduced the METH intake in the control animals but not in MAM animals. Ketamine effect on METH self-administration may be explained by increased glutamatergic signalling in the prefrontal cortex caused by the N-methyl-D-aspartate antagonism and disinhibition of GABA interneurons which was shown to be impaired in the MAM rats. This mechanism may at least partly explain the clinically proven anti-craving potential of ketamine and allow development of more specific anti-craving medications with fewer risks.

CEITEC Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Biomedical and Biotechnological Sciences Section of Pharmacology School of Medicine University of Catania Catania Italy

Department of Pharmacology Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Zobrazit více v PubMed

Neuropharmacology. 2008 Jun;54(8):1201-7 PubMed

Brain Res. 1992 Nov 6;595(1):121-7 PubMed

Psychopharmacology (Berl). 2008 Oct;200(2):205-15 PubMed

Front Pharmacol. 2014 Mar 20;5:44 PubMed

Ann N Y Acad Sci. 2012 Feb;1248:89-106 PubMed

Neuropharmacology. 2012 Mar;62(3):1359-70 PubMed

Life Sci. 2000 Jun 16;67(4):383-9 PubMed

J Psychopharmacol. 2011 Jun;25(6):822-35 PubMed

J Psychopharmacol. 2015 Jul;29(7):792-801 PubMed

Cochrane Database Syst Rev. 2014 Oct 14;(10 ):CD004837 PubMed

Alcohol. 2016 Aug;54:67-72 PubMed

Psychiatry Res. 2015 Feb 28;225(3):395-401 PubMed

Psychopharmacology (Berl). 2012 Jul;222(2):313-24 PubMed

Neuropsychopharmacology. 2000 Sep;23(3):223-39 PubMed

Cell Tissue Res. 2013 Oct;354(1):309-30 PubMed

Psychiatr Clin North Am. 2009 Dec;32(4):821-33 PubMed

Brain Res. 1990 Nov 19;533(2):348-52 PubMed

Brain Res Bull. 1997;44(3):221-7 PubMed

Biol Psychiatry. 2001 Jul 15;50(2):71-83 PubMed

World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):390-9 PubMed

Pharmacopsychiatry. 2008 Mar;41(2):54-9 PubMed

Psychopharmacology (Berl). 2015 Dec;232(23):4325-35 PubMed

NMR Biomed. 2011 Dec;24(10):1235-42 PubMed

Addict Biol. 2015 May;20(3):490-9 PubMed

Biol Psychiatry. 2014 Jul 1;76(1):40-6 PubMed

Neuropharmacology. 2016 Mar;102:72-9 PubMed

Behav Brain Res. 2014 Sep 1;271:111-5 PubMed

Neurosci Lett. 1992 Feb 17;136(1):39-42 PubMed

Front Psychiatry. 2015 Jul 06;6:91 PubMed

Neurosignals. 2006-2007;15(6):322-31 PubMed

Eur J Pharmacol. 2014 May 5;730:77-81 PubMed

Biol Psychiatry. 2017 Mar 15;81(6):503-513 PubMed

Neuropharmacology. 2016 Jan;100:17-26 PubMed

Behav Brain Res. 2009 Dec 7;204(2):306-12 PubMed

Psychopharmacology (Berl). 2016 Jun;233(12 ):2241-51 PubMed

Neuropsychopharmacology. 2002 Dec;27(6):889-905 PubMed

Depress Anxiety. 2016 Aug;33(8):689-97 PubMed

Pharmacol Biochem Behav. 2009 Oct;93(4):382-90 PubMed

World J Biol Psychiatry. 2017 Mar;18(2):129-142 PubMed

Neuroreport. 2004 Jan 19;15(1):203-6 PubMed

JAMA. 1990 Nov 21;264(19):2511-8 PubMed

Neuropharmacology. 2015 Oct;97:7-17 PubMed

Psychopharmacology (Berl). 2013 Mar;226(1):45-51 PubMed

Eur Neuropsychopharmacol. 2016 Dec;26(12 ):1989-1999 PubMed

Eur Neuropsychopharmacol. 2007 Dec;17(12):756-62 PubMed

Transl Psychiatry. 2015 Oct 27;5:e666 PubMed

Neuropharmacology. 2014 Dec;87:150-60 PubMed

Ann N Y Acad Sci. 2015 Mar;1338:38-57 PubMed

Int J Neuropsychopharmacol. 2012 Feb;15(1):69-76 PubMed

J Neuroimmune Pharmacol. 2012 Mar;7(1):113-39 PubMed

J Dual Diagn. 2014;10(1):52-7 PubMed

Brain Res. 1995 Mar 13;674(1):91-6 PubMed

Psychopharmacology (Berl). 2013 Nov;230(2):291-8 PubMed

Behav Brain Res. 2011 Apr 15;218(2):346-9 PubMed

Neuropsychopharmacology. 2004 Nov;29(11):2052-64 PubMed

Int J Neuropsychopharmacol. 2014 Oct 31;18(1):null PubMed

Psychiatry Res. 1998 May 20;82(2):107-14 PubMed

Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2026-36 PubMed

Neuro Endocrinol Lett. 2009;30(5):663-70 PubMed

Jpn J Pharmacol. 1995 Oct;69(2):83-90 PubMed

J Neurosci Res. 1998 Mar 1;51(5):583-92 PubMed

Drug Alcohol Depend. 2014 Mar 1;136:153-7 PubMed

Schizophr Res. 2017 Oct;188:132-140 PubMed

J Pharm Pract. 2014 Dec;27(6):582-6 PubMed

Pharmacol Biochem Behav. 2012 Feb;100(4):801-10 PubMed

Anesth Analg. 2003 Jan;96(1):148-52, table of contents PubMed

Neurosci Lett. 1998 Feb 13;242(2):114-6 PubMed

Ann N Y Acad Sci. 1992;668:350-2 PubMed

Neuropharmacology. 2001 Mar;40(4):482-90 PubMed

Acta Psychiatr Scand. 2009 Aug;120(2):85-96 PubMed

Neuropsychopharmacology. 2001 Oct;25(4):455-67 PubMed

NIDA Res Monogr. 1989;95:511 PubMed

Brain Res. 1991 May 24;549(2):230-5 PubMed

Recent Pat CNS Drug Discov. 2014 Apr;9(1):13-25 PubMed

Psychopharmacology (Berl). 2006 May;186(1):48-53 PubMed

Neuropsychopharmacology. 2016 Mar;41(4):1046-56 PubMed

Sci Rep. 2015 Jun 26;5:11611 PubMed

Front Neurosci. 2015 Jul 21;9:249 PubMed

Schizophr Res. 2014 May;155(1-3):45-51 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jul 3;52:79-85 PubMed

J Psychopharmacol. 2005 May;19(3):301-5 PubMed

Int J Neuropsychopharmacol. 2012 Nov;15(10):1503-11 PubMed

Psychopharmacology (Berl). 2007 Jun;192(3):373-83 PubMed

J Subst Abuse Treat. 2002 Dec;23(4):273-83 PubMed

Int J Neuropsychopharmacol. 2017 May 1;20(5):383-391 PubMed

Lancet Psychiatry. 2016 Aug;3(8):760-73 PubMed

Pharmacol Biochem Behav. 1993 Jan;44(1):245-7 PubMed

Curr Top Behav Neurosci. 2010;4:391-433 PubMed

J Neurosci. 2007 Oct 17;27(42):11424-30 PubMed

Int J Neuropsychopharmacol. 2016 Apr 20;19(4):null PubMed

Exp Clin Psychopharmacol. 2017 Apr;25(2):84-93 PubMed

Nature. 2011 Jun 15;475(7354):91-5 PubMed

Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model

The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology

Different effects of prenatal MAM vs. perinatal THC exposure on regional cerebral blood perfusion detected by Arterial Spin Labelling MRI in rats

Ghrelin Receptor Antagonism of Methamphetamine-Induced Conditioned Place Preference and Intravenous Self-Administration in Rats

Both ketamine and NBQX attenuate alcohol drinking in male Wistar rats